This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Scopus Google Scholar Articles by Hackett, G. I Social Bookmarking                         What's this?

Review: Androgens, erectile dysfunction and cardiovascular risk in type 2 diabetes

Good Hope Hospital, Sutton Coldfield, B75 7RR, UK, geoff.hackett{at}virgin.net

Men with type 2 diabetes now require annual assessment for erectile dysfunction, and this should include assessment for testosterone deficiency. Up to 40% of patients might be candidates for testosterone replacement for the treatment of bothersome symptoms including erectile dysfunction, lethargy, fatigue, loss of libido and depressed mood. There is emerging evidence that there may also be benefits in the primary care quality parameters for type 2 diabetes.

Key Words: erectile dysfunction • hypogonadism • NICE • Quality Outcome Framework • type 2 diabetes

References

• Home P., Mant J., Diaz J., Turner C. On behalf of the Guideline Development Group Management of type 2 diabetes: summary of updated NICE guidance. BMJ 2008;336:1306-08.[Free Full Text]
• Hackett G., Kell P., Ralph D. et al. British Society for Sexual Medicine Guidelines on the Management of Erectile Dysfunction. J Sex Med 2008;5:1841-6.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Wespes E., Amar E., Hatzichristou DG et al. EAU guidelines on erectile. dysfunction. Eur Urol 2002;41:1-5.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Kapoor D., Aldred H., Clark S. et al. Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: correlations with bioavailable testosterone and visceral adiposity. Diabetes Care 2007;30:911-17.[Abstract/Free Full Text]
• Connecting for Health: the 2004 GP contract. www.nhs.org.uk
• Dhindsa S., Prabhakar S., Sethi M. et al. Frequent occurrence of hypogonadotrophic hypogonadism in type 2 diabetes. J Clin End Metab 2004;89:5462-8.[Abstract/Free Full Text]
• Isidori AM, Caprio M., Strollo F. et al. Leptin and androgens in male obesity: evidence for leptin contribution to reduced androgen levels. J Clin Endocrinol Metab 1999;84:3673-80.[Abstract/Free Full Text]
• Andersson B., Marin P., Lissner L. et al. Testosterone concentrations in women and men with NIDDM. Diabetes Care 1994;17:405-11.[Abstract]
• Ozata M., Oktenli C., Cagatay O., Bingol N., Ozdemir IC The effects of metformin and diet on plasma testosterone and leptin levels in obese men. Obes Res 2001;9:662-7.[Web of Science][Medline] [Order article via Infotrieve]
• Connor E., Wedick NM, Wingard DL Endogenous sex hormones and the development of type 2 diabetes in older men and women; the Rancho Bernardo study. Diabetes Care 2002;25:55-60.[Abstract/Free Full Text]
• Shores MM, Matsumoto AM, Sloan KL et al. Low serum testosterone and mortality in male veterans. Arch Intern Med 2006;166:1660-5.[Abstract/Free Full Text]
• Khaw KT, Dowsett M., Folkerd E. et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European Prospective Investigation into Cancer in Norfolk (EPIC-Norfolk) prospective population study. Circulation 2007;116:2694-701.[Abstract/Free Full Text]
• Billups KL Erectile dysfunction as an early sign of cardiovascular disease. Int J Impot Res 2005;17(suppl 1):S19-24.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Gazzaruso C., Solerte SB, Pujia A. et al. Erectile dysfunction as a predictor of cardiovascular events and death in diabetic patients with angiographically proven asymptomatic coronary artery disease. J Am Coll Cardiol 2008;51:2040-4.[Abstract/Free Full Text]
• Thompson IM, Tangen CM, Goodman PJ et al. Erectile dysfunction and subsequent cardiovascular disease. JAMA 2005;294:2996-3002.[Abstract/Free Full Text]
• Montorsi F., Briganti A., Salonia A. et al. Erectile dysfunction prevalence, time of onset and association with risk factors in 300 consecutive patients with acute chest pain and angiographically documented coronary artery disease. Eur Urol 2003;44:360-5[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Ma RCW, So WY, Yang XL et al. Erectile dysfunction predicts coronary heart disease in type 2 diabetes. J Am Coll Cardiol 2008;51: 2045-50.[Abstract/Free Full Text]
• Rader DJ Effect of insulin resistance, dyslipidemia, and the intra-abdominal adiposity on the development of cardiovascular disease and diabetes mellitus. Am J Med 2007;120:512-18.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Kalinchenko SY, Kozlov GI, Gontcharov NP, Katsiya GV Oral testosterone undecanoate reverses erectile dysfunction associated with diabetes mellitus in patients failing on sildenafil citrate therapy alone. Aging Male 2003;6:94-9.[CrossRef][Medline] [Order article via Infotrieve]
• Shabsigh R., Kaufman J., Steidle J. et al. Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men who do not respond to sildenafil alone. J Urol 2004;172: 658-63.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Kapoor D., Goodwin E., Channer KS et al. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol 2006;154:899-906.[Abstract/Free Full Text]
• Kapoor D., Clarke S., Stanworth R. et al. The effect of testosterone replacement therapy on adipocytokines and C-reactive protein in hypogonadal men with type 2 diabetes. Eur J Endocrinol 2007;156: 595-602.[Abstract/Free Full Text]
• Naharci MI, Pinar M., Bolu E., Olgun A. Effect of testosterone on insulin sensitivity in men with idiopathic hypogonadotropic hypogonadism. Endocr Pract 2007;13:629-35.[Medline] [Order article via Infotrieve]
• Boyanov MA, Boneva Z., Christov VG Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male 2003;6:1-7.[Medline] [Order article via Infotrieve]
• Shabsigh R., Crawford ED, Nehra A., Slawin KM Testosterone therapy in hypogonadal men and potential prostate cancer risk: a systematic review. Int J Impot Res 2009;21:9-23.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]

The British Journal of Diabetes & Vascular Disease, Vol. 9, No. 5, 214-217 (2009)
DOI: 10.1177/1474651409340361


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				T. A Mahmood Influences of excess adiposity on reproductive function The British Journal of Diabetes & Vascular Disease, September 1, 2009; 9(5): 197 - 199. [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Scopus Google Scholar Articles by Hackett, G. I Social Bookmarking                         What's this?